Adma Biologics (ADMA) Stock Moves -0.15%: What You Should Know

Adma Biologics (ADMA) ended the recent trading session at $20.25, demonstrating a -0.15% swing from the preceding day's closing price. This move was narrower than the S&P 500's daily loss of 1.97%. On the other hand, the Dow registered a loss of 1.69%, and the technology-centric Nasdaq decreased by 2.7%.Shares of the infectious disease drug developer witnessed a gain of 31.35% over the previous month, beating the performance of the Medical sector with its loss of 2.45% and the S&P 500's loss of 2.79%.The upcoming earnings release of Adma Biologics will be of great interest to investors. The company's upcoming EPS is projected at $0.16, signifying a 100% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $119.1 million, indicating a 45.46% upward movement from the same quarter last year.For the full year, the Zacks Consensus Estimates are projecting earnings of $0.71 per share and revenue of $495.8 million, which would represent changes of +44.9% and +16.26%, respectively, from the prior year.Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 3.65% higher within the past month. Currently, Adma Biologics is carrying a Zacks Rank of #2 (Buy).In the context of valuation, Adma Biologics is at present trading with a Forward P/E ratio of 28.56. Its industry sports an average Forward P/E of 18.53, so one might conclude that Adma Biologics is trading at a premium comparatively.The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 71, positioning it in the top 29% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks